# Friedegund Meier

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/friedegund-meier/

## Facts

| Field | Value |
| --- | --- |
| Citations | 18,091 |
| Field | Cutaneous Melanoma Detection and Management |
| h-index | 71 |
| i10-index | 210 |
| Last Known Institution | National Center for Tumor Diseases |
| OpenAlex ID | https://openalex.org/A5037516725 |
| ORCID iD | https://orcid.org/0000-0003-4340-9706 |
| Works | 481 |

## Researcher papers

- [Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial](https://scholariq.org/papers/adjuvant-pembrolizumab-versus-placebo-in-resected-stage-iii-melanoma-eortc-1325/)

## Researcher topics

- [Cutaneous Melanoma Detection and Management](https://scholariq.org/topics/cutaneous-melanoma-detection-and-management/)
- [Melanoma and MAPK Pathways](https://scholariq.org/topics/melanoma-and-mapk-pathways/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Nonmelanoma Skin Cancer Studies](https://scholariq.org/topics/nonmelanoma-skin-cancer-studies/)
- [Immunotherapy and Immune Responses](https://scholariq.org/topics/immunotherapy-and-immune-responses/)

## Researcher university

- [National Center for Tumor Diseases](https://scholariq.org/institutions/national-center-for-tumor-diseases/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.